Cancer & Disease Research
Novel glioblastoma treatment shows promising results
Toronto’s University Health Network (UHN) neurosurgeons have developed a novel glioblastoma therapy that combines the injection of an oncolytic virus directly into the tumor with intravenous immunotherapy. The results, published Monday in Nature Medicine, found that this combination therapy prolonged survival rates, providing clinical benefits to over half of the patients studied. Read More
FDA approves first drug to treat agitation associated with dementia due to Alzheimer’s
The U.S. Food and Drug Administration (FDA) on Thursday announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. Read More
Video interview: Detecting potentially treatable causes of cognitive decline
In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may have reversible conditions that mimic dementia. Read More
Researchers map RNA to inform selection of stem cells for therapeutic applications
Creating maps of the RNA inside cells could improve cell therapies by enabling the isolation of subsets of cells with similar characteristics, according to a study published Friday in Cell Reports Methods. Read More
NIH launches investigation of somatic mosaicism in human cells and tissues
The National Institutes of Health (NIH) recently launched a new program: the Common Fund’s Somatic Mosaicism Across Human Tissues (SMaHT) Network. The program, with planned awards totaling $140 million over five years, aims to enhance knowledge of how much genetic variation exists within normal human cells and tissues throughout the body. Read More
CRISPR technique cuts time to develop mouse models with any cancer-causing gene
A CRISPR-based technique has cut the time it takes to create mouse models with mutations that cause cancer, making it easier to show the effects of genetic changes linked to tumor development. Read More
Researchers pitch cytokine-antibody complex as treatment for respiratory infections
Researchers have combined a cytokine and an antibody to generate inflammatory responses against viruses while minimizing tissue damage. Read More
Alzheimer’s drug could prevent damage to the brain
Researchers showed that tiny aggregates of amyloid beta protein, a naturally occurring substance associated with Alzheimer’s disease progression, can float freely through brain tissue fluid, reaching important brain regions and disrupting local neuron functioning. The research, published Wednesday in the journal Neuron, also indicated that a newly-approved Alzheimer’s disease treatment could neutralize these tiny aggregates, also known as protofibrils or oligomers. Read More
A closer look at long COVID symptoms
Patients with persistent neurological symptoms after SARS-CoV-2 infections were intensively studied and found to have autonomic dysfunction and differences in their immune cell profiles. The findings, published last Friday in Neurology: Neuroimmunology & Neuroinflammation, may help explain lingering long-COVID neurological symptoms, and lead to better diagnoses and treatments. Read More
Discovery of markers on long-lasting immune cells lights way to more durable vaccine responses
Researchers have identified surface markers on cells that continue producing antibodies for a long time, pointing to a way to improve the duration of response to vaccines. Read More
Conferences
International Paper Physics Conference 2023 (IPPC2023)
May 31 - June 2
Guangzhou, Guangdong China
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter